Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
An $80,000 grant from The Campbell Foundation will help scientist Natalia Freund continue her HIV vaccine studies.
Only HIV vax to show any efficacy prompted strong immune response in new study
They’re the 2019 recipients of amfAR’s Mathilde Krim Fellowship in Basic Biomedical Research.
These types of antibodies are able to neutralize a wide breadth of HIV strains.
New forms of treatment and PrEP and, hopefully, an at least partially effective vaccine will be key to fighting the epidemic in the 2020s.
“Young researchers such as myself…can provide a new perspective and contribute to the conversation for a cure,” says Chidera Ejikeme.
By altering the components of the vaccine regimen, researchers drove promising antibody and immune-cell responses.
Calling all U.S. cisgender gay and bi men and trans and gender nonconforming people at risk for the virus.
The ASCENT trial found that the vaccine regimen that was advanced to the forthcoming Mosaico trial prompted a strong immune response.
The Mosaico study will enroll gay and bisexual men and transgender people at significant risk for the virus.
Investigators led by Scripps Research will study vaccines that coax the immune system into creating antibodies that protect against HIV.
Federal researchers describe two paths to a vaccine—and one of them uses high-tech computers to design a vaccine candidate!
Researchers were also able to make the first-ever estimate of the level of antibodies needed for protection against HIV.
A new HIV vaccine prompts powerful antibody response in animals.
A better understanding of the three-part Env protein may help in the design of more effective vaccine candidates.
Researchers were also able to make the first-ever estimate of the level of antibodies needed for protection against the virus.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.